Table 1.
Characteristics | Clinical trial cohort (n = 45) n(%) | Real-world cohort (n = 55) n(%) | P-value |
---|---|---|---|
Age | 0.364 | ||
<60 | 34 (76) | 37 (67) | |
≥60 | 11 (24) | 18 (33) | |
Sex | 0.867 | ||
Male | 35 (78) | 42 (76) | |
Female | 10 (22) | 13 (24) | |
ECOG PS | 0.001* | ||
0 | 35 (78) | 25 (45) | |
1 | 10 (22) | 25 (45) | |
2 | 0 (0) | 5 (9) | |
Location | 0.118 | ||
GEJ | 9 (20) | 5 (9) | |
Non-GEJ | 36 (80) | 50 (91) | |
Stage | 0.108 | ||
III | 8 (18) | 4 (7) | |
IV | 37 (82) | 51 (93) | |
Lauren classification | 0.550 | ||
Intestinal type | 20 (61) | 10 (59) | |
Diffused type | 6 (18) | 5 (29) | |
Mixed type | 7 (21) | 2 (12) | |
Unknown | 12 | 38 | |
HER2 expression | 0.494* | ||
Positive | 0 (0) | 2 (5) | |
Negative | 39 (100) | 40 (95) | |
Unknown | 6 | 13 | |
Metastasis site | 0.036* | ||
Liver | 22 (49) | 24 (44) | |
Peritoneal | 6 (13) | 13 (24) | |
Bone | 6 (13) | 1 (2) | |
Pancreas | 0 (0) | 5 (9) | |
Abdominal wall | 0 (0) | 5 (9) | |
Colorectal | 1 (2) | 2 (4) | |
Ovary | 1 (2) | 2 (4) | |
Bladder | 2 (4) | 1 (2) | |
Others | 5 (11) | 6 (11) | |
MMR status | 0.485* | ||
pMMR | 31 (97) | 34 (100) | |
dMMR | 1 (3) | 0 (0) | |
Unknown | 13 | 21 | |
PD-L1 expression | 1* | ||
Positive | 8 (42) | 0 (0) | |
Negative | 11 (58) | 1 (100) | |
Unknown | 26 | 54 | |
Differentiation | 0.015 | ||
Poor | 15 (39) | 31 (66) | |
Moderate-well | 23 (61) | 16 (34) | |
Unknown | 7 | 8 | |
History of gastric cancer operation | 0.110 | ||
Yes | 7 (16) | 16 (29) | |
No | 38 (84) | 39 (71) | |
History of smoke | 0.099 | ||
Yes | 10 (23) | 21 (38) | |
No | 34 (77) | 34 (62) | |
Unknown | 1 | 0 | |
History of alcohol | 0.475 | ||
Yes | 10 (23) | 16 (29) | |
No | 34 (77) | 39 (71) | |
Unknown | 1 | 0 |
ECOG PS, Eastern Cooperative Oncology Group Performance Status; MMR, proficient mismatch; pMMR, proficient mismatch repair; dMMR, deficient mismatch repair.
*Fisher’s exact probability method.